Analyst Price Target is $1.50
▲ +543.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Alzamend Neuro in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 543.78% upside from the last price of $0.23.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Alzamend Neuro. This Buy consensus rating has held steady for over two years.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.